High expression of SHP2 predicts a promising prognosis in colorectal cancer

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Src homology 2 domain-containing phosphatase 2 (SHP2) is implicated in solid tumor progression.
• Previous studies suggest a link between SHP2 expression and colorectal cancer (CRC) prognosis, but large-scale validation is needed.

Purpose of the Study:

• To investigate the prognostic value of SHP2 expression in a large cohort of colorectal cancer patients.
• To correlate SHP2 expression levels with clinicopathological features and patient survival.

Main Methods:

• Tissue microarrays of 860 CRCs and 197 adjacent normal tissues were analyzed using immunohistochemistry for SHP2 expression.
• Statistical analyses included Kaplan-Meier curves, log-rank tests, and Cox regression models for prognostic factor evaluation.

Main Results:

• SHP2 expression was significantly higher in CRC tissues compared to adjacent normal tissues (P < 0.001).
• Elevated SHP2 levels correlated with tumor differentiation, invasion depth, metastasis, vascular invasion, lymph node involvement, and TNM stage (P < 0.05).
• High SHP2 expression was associated with significantly better overall survival (P = 0.008) and identified as an independent favorable prognostic factor in multivariate analysis (P = 0.033).

Conclusions:

• SHP2 is upregulated in colorectal cancer tissues.
• High SHP2 expression is linked to improved patient outcomes and may serve as a favorable prognostic biomarker for CRC.